Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 9 ... differences in this system in humans might partly explain the variable success rate of Tuberculosis vaccination programmes around the world." One way to make a good vaccine ...
Subject: Biotechnology and Biological Sciences Research Council
2009 NOV 23 ... and Vaccine Immunology (Adjuvants Induce Distinct Immunological Phenotypes in a Bovine Tuberculosis Vaccine Model. Clinical and Vaccine Immunology, 2009;16(10):1443-1448). For ...
2009 NOV 2 ... Clinical and Vaccine Immunology, "In the search for better tools to control bovine tuberculosis, the development of diagnostic tests with improved specificity and sensitivity has a ...
2009 NOV 16 ... to make significant investments in our commercial product pipeline, most notably our tuberculosis candidate, which is in a Phase IIb efficacy trial in South Africa. In addition, we ... through September 2011. We are conducting ongoing development work on several of our vaccine and therapeutic candidates in our anthrax program under various development contracts ...
2009 NOV 23 ... "T-SPOT.TB is a specific assay for the diagnosis of tuberculosis. The assay needs to be performed with freshly isolated cells, and interpretation ... T-SPOT.TB." Franken and colleagues published their study in Clinical and Vaccine Immunology (Variation in T-SPOT.TB Spot Interpretation between Independent Observers ...
2009 OCT 12 ... guinea pigs following low-dose, pulmonary exposure to virulent Mycobacterium tuberculosis. After purified protein derivative (PPD) stimulation, the levels of lung cell ... our results suggest that type I cytokine mRNA expression is not associated with vaccine-induced protection in the low-dose guinea pig model of tuberculosis." ...
2009 NOV 2 ... bovis cultures contain molecules which could promote protective immunity to tuberculosis in animals. Different protein fractions of M. bovis cultures were obtained by elution ... tuberculosis." Meikle and colleagues published their study in Clinical and Vaccine Immunology (Identification of Novel Mycobacterium bovis Antigens by Dissection of Crude ...
2009 NOV 23 ... "Deer are acknowledged as hosts of Mycobacterium bovis, the causative agent of bovine tuberculosis (bTB), and determining the prevalence of infection in deer species is one of the key ... Gowtagesequeira and colleagues published their study in Clinical and Vaccine Immunology (Evaluation of the CervidTB STAT-PAK for the Detection of Mycobacterium bovis ...
2009 NOV 16 ... in the poorest countries, and collectively cause a health burden comparable to malaria, tuberculosis or AIDS (known as the "Big 3" tropical diseases). The McLaughlin Rotman ... United Cell Biotechnology Co. Ltd. (Shanghai, China) manufactures a novel oral cholera vaccine, as does Shantha Biotechnics (Hyderabad, India), whose product provides longer, broader ...
2009 NOV 23 ... New investigation results, 'New alternative vaccine component against mycobacterium tuberculosis--heat shock protein 16.3 or its T-cell epitope,' are detailed in a study published in ...
2009 NOV 1 ... Parkville, BCG Vaccines, Bacillus Calmette-Guerin Vaccines, Biotechnology, Cutaneous Tuberculosis, Drugs, Immunization, Isoniazid, Mycobacteria, Mycobacterium Tuberculosis, ... girl was inadvertently immunised with an excessively large dose of BCG-Connaught vaccine (1.0 ml instead of 0.1 ml). Examination of the patient a few hours later revealed a ...
2009 OCT 12 ... vectors has been developed to generate more effective vaccines for AIDS, malaria, and tuberculosis. Although these vectors elicit potent T cell responses, the mechanisms by which they ... elicits CD8(+) cells with different fine specificities and kinetics of mobilization. Vaccine-induced CD8(+) T cells recognized overlapping third V region loop peptides. ...
2009 OCT 12 ... A new study, 'Inactivation of the ilvB1 gene in Mycobacterium tuberculosis leads to branched-chain amino acid auxotrophy and attenuation of virulence in mice,' is ... could persist in the infected mice for a long time, and therefore could be a potential vaccine candidate." Awasthy and colleagues published their study in Microbiology ...
2009 NOV 9 ... "Many international organizations are advocating for new funds for tuberculosis (TB) specific interventions. Although this approach should help reduce TB incidence, ... Virology, McGill University. This article was prepared by AIDS Vaccine Week editors from staff and other reports. Copyright 2009, AIDS Vaccine Week via ...
2009 OCT 19 ... HPV DNA vaccines, SigmE7/MtHSP70 and SigmE7/HuHSP70, using human and Mycobacterium tuberculosis HSP70 linked, respectively, to HPV16 mE7 and the signal peptide gene of human CD33. Our ... A new study, 'Human HSP70 and modified HPV16 E7 fusion DNA vaccine induces enhanced specific CD8+ T cell responses and anti-tumor effects,' is now ...
2009 NOV 23 ... of Mycobacterium bovis bacillus Calmette-Guerin (BCG) emphasize the need for alternative tuberculosis (TB) vaccines. DNA vaccines are interesting candidates but are limited by the restricted ... and cellular immunology have paved the way toward the rational design of an efficacious vaccine. We exploited self-cleaving peptide 2A from the foot-and-mouth disease virus, because of ...
2009 OCT 19 ... an ambitious portfolio of novel vaccines, drug regimens, and diagnostic tools for tuberculosis (TB). We elicited the expected efficacies and improvements of the novel interventions in ... focusing on the WHO Southeast Asia region. Neonatal vaccination with the portfolio vaccine decreases TB incidence by 39% to 52% by 2050. Drug regimens that shorten treatment ...
2009 NOV 2 ... Unblinded analysis of sera from an additional 895 animals in 10 accredited bovine tuberculosis-free states revealed 98% specificity overall," wrote L.R. Green and colleagues. ... Green and colleagues published the results of their research in Clinical and Vaccine Immunology (Single-Antigen Serological Testing for Bovine Tuberculosis. Clinical and ...
2009 OCT 12 ... bovis Bacillus Calmette Guerin (BCG) vaccine to protect against murine model of tuberculosis. Although identified as having effects on macrophage presentation events, lactoferrin's ...
